SCGE Management’s Affirm AFRM Stock Holding History

SCGE Management’s Portfolio AFRM Stock Details AFRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-20,000	Closed	-$926K	–	27
2022 Q1	$926K	Hold	20,000	–	–	0.01%	33
2021 Q4	$2.01M	Hold	20,000	–	–	0.02%	32
2021 Q3	$2.38M	Hold	20,000	–	–	0.02%	39
2021 Q2	$1.35M	Hold	20,000	–	–	0.01%	37
2021 Q1	$1.41M	Buy	+20,000	New	+$1.94M	0.02%	33

Other funds holding AFRM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SCGE Management's AFRM Position: Q2 2022 in Review

SCGE Management sold out of Affirm (AFRM) in Q2 2022, closing a stake of 20,000 shares — an estimated $926K sold.

SCGE Management first reported a position in AFRM in Q1 2021 and held it in 5 quarters. The position peaked at $2.38M in Q3 2021. 347 funds tracked by Wall St. Rank hold AFRM as of Q2 2022.

SCGE Management reported no remaining Affirm position as of Q2 2022 after selling out during the quarter.
SCGE Management sold 20,000 Affirm shares in Q2 2022, an estimated $926K.
SCGE Management first reported a position in Affirm in Q1 2021 and held it in 5 quarters.
SCGE Management's Affirm position peaked at $2.38M in Q3 2021.
347 funds tracked by Wall St. Rank held Affirm as of Q2 2022.

Based on SCGE Management's 13F filing for Q2 2022, filed 15 Aug 2022.